Poly Medicure Limited
Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate,
Phase-III, New Delhi - 110 020 (INDIA)
T: +91-11- 33550700, 47317000
E: info@polymedicure.com W: polymedicure.com
CIN: L 40300DL1995PLC066923

POLYMED

Date: 03rd September, 2025

Scrip Code: - 531768

The Manager,
BSE Limited,
Department of Corporate Services,
Phirozee Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

Scrip Code:- POLYMED

The Manager
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1-Block-G
Bandra Kurla Complex, Bandra(E),
Mumbai-400051.

Sub: Submission of Investor's Presentation on Acquisition of Pendracare Group (a unique interventional cardiology consumable asset in Europe.

Dear Sir/Madam,

Pursuant to Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Investor's Presentation on Acquisition of Pendracare Group (a unique interventional cardiology consumable asset in Europe).

The same is also available on the website of company i.e. www.polymedicure.com .

Request you to take the same on records.

Thanking You,
Yours Sincerely

For **Poly Medicure Limited**

AVINASH CHANDRA
Digitally signed by AVINASH CHANDRA
Date: 2025.09.03 18:12:39 +05'30'

POLY MEDICURE LTD. New Delhi

Avinash Chandra
Company Secretary
M. No. A32270

Acquisition of Pendracare Group

A unique interventional cardiology consumable asset in Europe

---

Investor Presentation

September 2025



Polymed : India's Leading MedTech Company

Polymed at a Glance

12
Specialities

~12
Manufacturing Plants
Across 4 countries

125+
Countries

200+
Medical Devices

3000+
Employee Base

530+
Sales Associates

334
Patents Granted

900+
Distributors across
India & Globally

1.8 Billion+
Devices Manufacturing Capacity
Per year

POLYMED

Navigating the Path

Building Tomorrow's Healthcare Solutions

Started In

1997

Commencement of Manufacturing Operation

Transition

Value Based Supplier

2002-09

Product and facility expansion

Preferred Supplier

Supplier of 1st Choice

2011-19

New R&D Center, Acq of Plan 1 Health, New Manufacturing Plants

Solutions Partner

Driving Delivery of Health Care

2020-24

- Launched **differentiated products** in premium markets & geographies
- Accelerate **growth** in developed markets

2025 - 27

- Prioritize the expansion of **transformative verticals** – Cardiology, Critical Care, Oncology, Renal Care
- Expand global footprint with direct presence

2028 & beyond

- Through a strategic focus on continuous **innovation**, global expansion, we will drive **sustainable growth**, enhance patient outcomes, and aim to solidify our presence in the medical device industry.

POLYMED

Our Innovations Deliver Care to Key Clinical Specialties



Polymed’s Ecosystem (Manufacturing Process)



- Clinical Support
- Distribution Network
- Sales & Marketing

- Product Concept
- Product Design
- Rapid Prototyping
- Regulatory
- Compliance

- Product Manufacturing
- Product Packaging
- Sterilization

- Tool Design
- Tool Manufacturing

Polymed's Manufacturing Footprint

12 Facilities across 3 continents

117,Faridabad, India

IMT 1,Faridabad, India


SEZ 2, Jaipur, India


115-116, Faridabad Plant, India


SEZ 1 Jaipur, India


Laiyang-qingdao, China

104-105,Faridabad Plant, India


R & D Centre, India


Amaro, Italy


Haridwar Plant, India


Assuit, Egypt


IMT 2, Faridabad India

12 Plants

Company with **international manufacturing facilities**

350+ Moulding Machines and 1500+ Molds & Dies

200+ Automatic Assembly Machines

100+ Robots employed in our manufacturing processes

POLYMED

Way Forward

Research & Development

- Targeted R&D investments towards transformative therapeutic areas, aiming towards innovations
- Integration of AI and IoT technologies to enhance efficiency & precision

Emphasizing Inorganic Growth

Strategic Alliances to foster synergies and expanding market reach

International Strategy

Improve brand visibility & enhance direct presence to gain deeper insights into local market dynamics

Manufacturing

Enhance manufacturing capacity to meet growing global demand

Clinical Footprint

Targeted clinical engagements with key stakeholders, fostering innovation and enhancement of patient outcomes

Protect Our Planet

Implementing sustainable practices across all operations, aiming to minimize environmental impact

Robust Growth Backed by Solid Balance Sheet...

Amount in INR Cr.













* Excludes the amount raised through QIP in August 2024, EBIT has been computed after excluding the treasury income generated from the QIP Funds

POLYMED

PendraCare : Unique interventional cardiology asset

Executive **Summary**

Brief Overview	• Located at Leek (Netherlands), specializing in cardiology catheter-based technologies • **One of the few fully integrated independent player of size and scale in Europe in its space** • Develops, manufactures and sells innovative catheter solutions; also provide design, development and manufacturing services to other OEM's. Sales under its own brand as well as supplier to some of the worlds largest OEM's • Registered in more then 60 countries (CE / FDA / CFDA / ANVISA) • **Pendracare Proforma Financials**: CY24 Revenue : EUR.9.9 million I Gross Profit : EUR 7.3 million I EBITDA : EUR 1.4 million I PBT : EUR 801k
Products	• Guiding Catheters, Angiographic Catheters • Semi-finished : Range of Guiding and Diagnostic catheter parts and sub assemblies • Contract Development for catheter products
Transaction Overview	• Acquiring Pendracare Group **("Group")** consisting Pendracare Holdings and Wellinq Medical from Wellinq Holdings • Floris Alkemade (Founder- non executive) 80% stake and Sander Hartman (CEO) 20% stake are beneficial owners • Existing Management to continue; Sander to continue as the Managing Director / CEO • Acquiring 90% of the Group for an upfront equity consideration of ~Euro 11mn; inter-group loan liabilities of Euro 3.2mn as of June 30, 2025 to be repaid; **total upfront payout of ~Euro 14.2mn**; taking over net external debt of Euro 2.9mn • **EV/Revenue and EV/EBITDA (CY 2024) of 1.83x and 13x respectively** • Certain earn-out payments to be made subject to achievement of certain milestones over the next 4-5 years • Balance 10% stake, held by Sander, to be acquired in 2030 basis actual EBITDA of CY 2029
Status and Next Steps	▪ Customary transaction closure activities to be completed including closing adjustments ▪ Expected to be closed in next 4-8 weeks ▪ To be funded by cash balances and internal accruals

POLYMED

Pendracare – A Unique Interventional Cardiology consumable business in Europe

Pendracare – One-of-a-kind opportunity

Located in **Leek Netherlands**

Product registration in more than 60 countries (CE / FDA / CFDA / ANVISA)

Trusted Global Supplier to medical devices industry leaders

67 employees

One of the few independent player of size and scale in Europe specializing in cardiology catheter business

Capacity of >1.5 million products per year; Current production is 700-800k units per year

CY24 Revenue : EUR.9.9 million
EBITDA : EUR 1.4 million

With diversified revenue base

Core Business Split, CY24



- **Operating across 35+ countries with 50+ distributors** across Europe, Middle East and Latin America.
- **Long term relationships with leading global OEMs** for product manufacturing and distribution
- Recently partnered with a European medical device company for **development and distribution of products used in the structural heart segment**
- In discussion with another US based company for development of neuro segment products

Backed by strong management

Sander Hartman –
CEO / Founder
In Pendracare since 2012
~20+ years of work experience

Thea van Leersum –
Manager Sales and Supply Chain
In Pendracare since 2008
~20+ years of experience

Erendira Rodriguez –
Director QA-RA and clinical
In Pendracare since 2019
~15+ years of experience

Han Post –
Manager R&D
In Pendracare since 2019
~25+ years of experience

Wendy Melchior –
HR Director
In Pendracare since 2018
~25+ years of experience

POLYMED

Well Established Products with regulatory approvals in key markets

Product	Description	Photos	OEM	Distributor
Guiding Catheter (GC)	• **CE marked & FDA approved** • 2.5-year ARCUS-IMPROVE clinical data • Radial access design: hydrophilic coating & support		✓	✓
Diagnostic Catheter (DC)	**CE marked** Superior body characteristics, excellent torque and high flow rate		✓	✓
Semi - Finished	• Guiding & diagnostic catheter components • Licensing model for end-product finalization		✓	
CD/CM	• Catheter Contract Development • OEM manufacturing of braided catheters		✓	

Manufacturing Facility

Leek, Netherlands







ISO 13485 and FDA approved manufacturing

3,800 m^2 Leased facility (across 3 locations)

1,150 m^2 Cleanroom

>1.5 million production capacity per year

New lease signed ~2300m^2 for consolidating operations at one location; transition expected in CY 2028

Significant synergies potential and platform for global expansion of cardiology business

Expect to generate annual EBITDA synergy of EUR 3-4 million in next 3-4 years

1

Manufacturing and Procurement Synergy

Cost synergies expected in procurement and production processes

2

Expansion of Distribution Network

Expanding sales through leveraging Polymed's distribution network including in India

3

Leverage existing relationships

Leveraging Pendracare distributor relationships to drive Polymed's cardiology product sales

4

Direct access to European market

Deepening European presence for Polymed's existing product portfolio

POLYMED

Transaction rationale - Strategic asset provides platform for expansion of cardiology business globally

Strategic Asset

- One of the few independent cardiology consumable business in Europe
- Fits well with Polymed's strategy to grow cardiology business through strong R&D and manufacturing capabilities in ancillary cardiology consumables segment

Regulatory approvals in key markets

- CE and FDA (for Guiding catheter) marked products

Made in Europe

- Well established European manufacturing base, enabling localized production and distribution of our products.



Existing relationships with key global med-tech customers

- Established long term relationship with leading global medical devices companies

Significant Potential Synergies

- Leverage Polymed's manufacturing and procurement capabilities to drive cost efficiencies
- Expansion of distribution network through Polymed's reach
- Deepen presence in Europe for existing and new launches

Platform for Global expansion

- Provides a platform to globally scale our cardiology business—leveraging local manufacturing, existing product lines, distribution, and operational capabilities.

POLYMED

Thank You

Poly Medicure Limited

Registered Office:
232 B, 3rd Floor, Okhla Industrial Estate, Phase III, New Delhi-110020, India
Tel:- 91-11-33550700, 47317000, 26321838/99
For any general queries, Reach us at:
info@polymedicure.com
Visit: www.polymedicure.com